Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Vanda Pharmaceuticals (VNDA) PT Raised to $13 at Cantor Fitzgerald
August 1, 2024 6:35 AM EDTCantor Fitzgerald analyst Charles Duncan raised the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $13.00 (from $11.00) while maintaining a Overweight rating.
The analyst comments "Overall, we see VNDA as a differentiated Neuro-Innovator with a broadening neuropsych portfolio that should garner investors' interest as... More
